PICC Property and Casualty (人保财险), the general-insurance subsidiary of state-owned PICC Group, signed China’s first commercial insurance policy covering invasive brain-computer interface surgery on Wednesday 12 August 2026. The counterparty is the Second Affiliated Hospital of Zhejiang University School of Medicine (浙江大学医学院附属第二医院, SAHZU) in Hangzhou.
The product is a custom surgical accident indemnity policy (侵入式脑机接口手术意外险) covering three named risks: intraoperative trauma (术中创伤), post-operative infection (术后感染), and diagnostic or medical error (诊疗过失). The product sits alongside basic medical insurance (基本医保) and inclusive commercial health cover (普惠健康险).
Disclosed and undisclosed terms
Disclosed: the underwriter, the hospital counterparty, the three named risks, and the fact that this is the first custom commercial insurance product built specifically for invasive BCI surgery in China. Not disclosed: the premium, the coverage cap, the identity of the first insured patient, the identity of the implanted BCI device, or the date of the first insured procedure.
The only publicly reported invasive BCI authorised in China to date is Neuracle’s NEO system, which received NMPA registration on 13 March 2026 and whose first commercial prescription was written at Huashan Hospital, Fudan University, on 13 July 2026. Neither PICC nor SAHZU has named a specific device or manufacturer in connection with this policy.
The Zhejiang provincial policy released the same day
Zhejiang Provincial Government Office released “Measures on Advancing BCI Industry-Academia-Research Coordination” (关于推进脑机接口产学研联动的若干措施) on the same day. Xinhua’s coverage identifies a five-node industrial layout: Hangzhou as the core, Ningbo for advanced materials and manufacturing, Wenzhou for clinical demonstration, Jiaxing for components, and Shaoxing for chip fabrication and packaging. Named support measures include innovative-medical-technology insurance incentives, government procurement promotion, and preclinical R&D subsidies of up to RMB 8 million per project.
Market reaction
Hong Kong and Shenzhen BCI-tagged equities moved on Wednesday. The Hong Kong BCI sector closed +1.59%. Shanghai Heartcare Medical Technology rose +1.28%. BrainAurora Medical Technology rose +1.65%. Innovation Medical (创新医疗, Shenzhen 002173) closed at its 10% daily limit. Aipeng Medical, Sanbo Brain Science, Weisi Medical, and Xiangyu Medical also traded higher.
The move follows the 28 July 2026 Chinese BCI concept-stock rally that InsideBCI covered. SCMP attributes flow to domestic Chinese retail buying.
Where this sits in the Chinese BCI commercial arc
Issue 01 of the Dargentic Intelligence Report classified China as one of the four global regulatory postures under the Industrial Builder frame. The 12 August package adds a commercial insurance product to that picture. The policy covers one hospital under one custom contract with one underwriter. Whether other Chinese hospitals with active invasive BCI programs (Huashan, Xuanwu, others) obtain similar coverage in the coming months will determine whether this becomes a general commercial-insurance category or stays a single-hospital pilot.
What to watch
Whether the Zhejiang provincial support measures translate into named projects and disbursements. The published Measures set the intent. The next indicator is the first RMB 8 million preclinical subsidy actually awarded.
Whether the eventual first insured procedure is disclosed publicly. The premium and coverage cap will define how Chinese insurers price the commercial risk of invasive neural implantation. InsideBCI has not identified a comparable Western commercial insurance product for invasive BCI surgery.